Histone-based liquid biopsy discriminates between myelodysplastic syndrome and solid malignancies
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F86652079%3A_____%2F25%3A00642521" target="_blank" >RIV/86652079:_____/25:00642521 - isvavai.cz</a>
Result on the web
<a href="https://link.springer.com/article/10.1186/s13148-025-01995-w" target="_blank" >https://link.springer.com/article/10.1186/s13148-025-01995-w</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1186/s13148-025-01995-w" target="_blank" >10.1186/s13148-025-01995-w</a>
Alternative languages
Result language
angličtina
Original language name
Histone-based liquid biopsy discriminates between myelodysplastic syndrome and solid malignancies
Original language description
Background Cancers can be hematological or solid, sharing many hallmarks, although their clinical behaviors are distinct. Identifying biomarkers that differentiate hematological from non-hematological malignancies could aid differential diagnosis by providing the basis for developing point-of-care diagnostic devices. In this respect, complex histone populations are secreted and detectable in biological fluids in various disease settings. To our knowledge, studies analyzing the circulating histone profile complexity by comparing healthy individuals, patients with hematological malignancies, and solid cancer patients are currently lacking. Results We assessed the plasma histone signature of healthy subjects (n = 30), and of patients with myelodysplastic syndrome (MDS, n = 43), colorectal cancer (CRC, n = 39), lung cancer (non-small cell lung cancer [NSCLC, n = 15]), small cell lung cancer [SCLC, n = 4]), or breast cancer [BC, n = 16]). Principal component analysis (PCA) demonstrated the segregation of circulating histones and histone complexes between oncological and healthy patients. Individual histones (H2A, H2B, H3, H4, macroH2A1.1, and macroH2A1.2), histone dimers and nucleosomes were assayed by ImageStream(X)-advanced flow cytometry. We found general increases in circulating histone abundance in the blood of cancer patients versus healthy controls. MDS and solid cancers could be discriminated among themselves for an increased abundance of histones H2A and macroH2A1.2 (p < 0.01), and a decreased abundance of H2A/H2B/H3/H4 and H3/H4 histone complexes (p < 0.01). Moreover, macroH2A1.2 and H2A/H2B/H3/H4 levels negatively or positively correlated with age in healthy subjects versus MDS patients, respectively. Conclusions Overall, we identified circulating histone signatures able to discriminate between solid and MDS, using a rapid and non-invasive imaging technology, which may improve patient diagnosis.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Clinical Epigenetics
ISSN
1868-7075
e-ISSN
1868-7083
Volume of the periodical
17
Issue of the periodical within the volume
1
Country of publishing house
GB - UNITED KINGDOM
Number of pages
13
Pages from-to
199
UT code for WoS article
001620853000001
EID of the result in the Scopus database
2-s2.0-105022626847